Bioventus (BVS) Liabilities from Discontinued Operations (2022)
Bioventus' (BVS) quarterly Liabilities from Discontinued Operations came in at $228.9 million in Q4 2022.
Powered by 
Analysis
Bioventus (BVS) Liabilities from Discontinued Operations (2022) Analysis & Trends
Bioventus (BVS) has reported Liabilities from Discontinued Operations for 1 consecutive years, with $228.9 million the latest figure, recorded in Q4 2022.
- For the quarter ending Q4 2022, Liabilities from Discontinued Operations changed N/A year-over-year to $228.9 million; the trailing twelve-month figure through Dec 2022 stood at $228.9 million (changed N/A YoY), and the FY2022 full-year result was $228.9 million, changed N/A from the prior year.
- Liabilities from Discontinued Operations steadied at $228.9 million in Q4 2022 per BVS's latest filing.
- Across five years, Liabilities from Discontinued Operations topped out at $228.9 million in Q4 2022 and bottomed at $228.9 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | Bioventus | 923.70 Mn | 894.24 Mn | 105.67 Mn |